Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 487423, 15 pages
http://dx.doi.org/10.1155/2012/487423
Research Article

Morinda citrifolia (Noni) Juice Augments Mammary Gland Differentiation and Reduces Mammary Tumor Growth in Mice Expressing the Unactivated c-erbB2 Transgene

1Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282, USA
2Division of Clinical, Social, and Administrative Sciences, Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA 15282, USA
3Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC 27127, USA
4Department of Obstetrics & Gynecology, McMaster University, Hamiton, ON, Canada L8S 4K1
5Barnes Center, Center for Applied Research & Intellectual Property Development, Clarion University, 840 Wood Street, Clarion, PA 16214-1232, USA

Received 29 December 2011; Accepted 2 February 2012

Academic Editor: Il-Moo Chang

Copyright © 2012 William P. Clafshenkel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Morinda citrifolia (noni) is reported to have many beneficial properties, including on immune, inflammatory, quality of life, and cancer endpoints, but little is known about its ability to prevent or treat breast cancer. To test its anticancer potential, the effects of Tahitian Noni Juice (TNJ) on mammary carcinogenesis were examined in MMTV-neu transgenic mice. Mammary tumor latency, incidence, multiplicity, and metastatic incidence were unaffected by TNJ treatment, which suggests that it would not increase or decrease breast cancer risk in women taking TNJ for its other benefits. However, noni may be useful to enhance treatment responses in women with existing HER2/neu breast cancer since TNJ resulted in significant reductions in tumor weight and volume and in longer tumor doubling times in mice. Remarkably, its ability to inhibit the growth of this aggressive form of cancer occurred with the mouse equivalent of a recommended dose for humans (<3 oz/day). A 30-day treatment with TNJ also induced significant changes in mammary secondary ductule branching and lobuloalveolar development, serum progesterone levels, and estrous cycling. Additional studies investigating TNJ-induced tumor growth suppression and modified reproductive responses are needed to characterize its potential as a CAM therapy for women with and without HER breast cancer.